NASDAQ:TARS | Free Cash Flow | Tarsus Pharmaceuticals, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$24.65M$5.82M-$30.47M
2025-12-31$19.33M$6.36M$12.97M
2025-03-31-$20.65M$590,000.00-$21.24M
2024-12-31-$22.18M$72,000.00-$22.25M
2024-03-31-$37.79M$174,000.00-$37.96M
2023-12-31-$39.34M$0.00-$39.34M
2023-03-31-$21.97M$340,000.00-$22.31M
2022-12-31-$10.87M$127,000.00-$11M
2022-03-31-$15.29M$161,000.00-$15.45M
2021-12-31-$12.12M$274,000.00-$12.4M
2021-03-31-$11.79M$175,000.00-$11.97M-115.35%
2020-12-31-$10.01M-$50,000.00-$10.06M
2020-03-31-$2M$36,000.00-$2.03M
2019-12-31-$806,000.00$24,000.00-$830,000.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$12.45M$9.86M-$22.31M
2024-12-31-$83.03M$1.57M-$84.59M
2023-12-31-$117.49M$1.5M-$119M
2022-12-31-$49.03M$506,000.00-$49.54M
2021-12-31$3.75M$586,000.00$3.16M
2020-12-31-$21.14M$456,000.00-$21.59M
2019-12-31-$3.67M$175,000.00-$3.85M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.